Company: BIAF
Filing Date: 2025-10-27
Form Type: PRER14A
Source: 0001493152-25-019752
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-27
Form: PRER14A
Chunk 3
---
 DECEMBER 19, 2025

GENERAL INFORMATION</div>

The Board of Directors (the “ Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “ Company”), is soliciting proxies to be used at a Special Meeting of Stockholders to be held on Friday, December 19, 2025, at 8:00 a.m. Central Time (the “ Special Meeting”) at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217. This proxy statement (this “ Proxy Statement”) and the accompanying proxy card are posted on the internet at www.proxyvote.com, and will be mailed to our stockholders on or about November [ ], 2025. If you previously requested electronic or paper delivery of the proxy materials, you will be sent this Proxy Statement, the accompanying proxy card on or about November [ ], 2025.

Voting Matters and the Board’s Recommendation

| Agenda                                                                                                                                  
 Item                                                                                                                                    |     | Board          
 Vote           
 Recommendation |     |      Page 
 Reference |
| Approval of the issuance                                                                                                                
 of up to an aggregate of 271,500 shares of our Common Stock upon the exercise of our August 2025 Warrants that may be equal to or       
 exceed 20% of our Common Stock outstanding before such offering (the “Warrant Exercise Proposal”)                                       |     | FOR            |     |         6 |
| Approval of an anti-dilution                                                                                                            
 provision of the August 2025 Warrants and the reduction in the exercise price of the August 2025 Warrants (subject to a floor price     
 of $4.50 per share) and corresponding increase in the number of shares issuable upon exercise thereof up to an aggregate maximum        
 of 365,620 shares of our Common Stock, resulting from the triggering of such anti-dilution provision (the “Warrant Anti-Dilution        
 Adjustment Proposal”).                                                                                                                  |     | FOR            |     |         8 |
| Approval of an anti-dilution                                                                                                            
 provision of the Series B Preferred Stock and the reduction in the exercise price of the Series B Preferred Stock (subject to a floor   
 price of $3.00 per share) and corresponding increase in the number of shares of Common Stock issuable upon conversion of the Series     
 B Preferred Stock thereof up to an aggregate of 131,884 shares of our Common Stock, resulting from the triggering of such anti-dilution 
 provision (the “Series